Daraxonrasib combination shows early promise in metastatic pancreatic cancer trial
publishers 20articles 24first reported 19 Nov, 13:01 UTCdeveloping since 19 Nov · 4 editions
An experimental daily pill combined with chemotherapy produced encouraging responses in an early-stage trial involving 61 patients with newly diagnosed metastatic pancreatic cancer.
In the phase 1/2 study, daraxonrasib was given with gemcitabine and nab-paclitaxel. Tumours shrank or became undetectable in 60.7% of patients, while 90.2% achieved disease control, meaning their cancer shrank or stopped growing. Five patients, or 8.2%, had complete radiological responses, with no detectable tumours on CT scans.
After a median follow-up of 18 months, 76.6% of participants were alive one year after starting treatment. The median period before tumours returned or began growing again was 12.8 months. The findings were presented by Dr Wungki Park of Memorial Sloan Kettering Cancer Center at a cancer research symposium in Barcelona.
Daraxonrasib inhibits mutated KRAS proteins, which drive growth in most pancreatic cancers. Researchers cautioned that an undetectable tumour on imaging does not establish that a patient has been cured, and longer follow-up is needed to determine how durable the responses are.
The results come from a small, early-stage study rather than a randomized comparison with chemotherapy alone. Larger trials will be needed to confirm the drug combination’s effectiveness and safety.
HOW THIS STORY WAS MADE
Written from 8 articles, 3 with the publisher's own text; 8 independent newsrooms once syndicated copies count as one (7 if wire copies count as one too); this version written 48 h after the record first saw the story; the editor kept it as written.
- Publishers
- 20
- Source articles
- 24
- Given to the writer
- 8, 3 with the article's own text
- Independent newsrooms
- 8 (7 if wire copies count as one)
- This version written
- 48 h after the record first saw the story
- Second model (editor)
- kept as written
- Publication gate
- passed
- Human review
- none
WHAT THE EDITOR DID
The second model checked the writer's draft against the same sources and published it as written.
Written by a language model from the sources above, then checked by a second model that may only cut, attribute or correct. How it works →